Loading clinical trials...
Loading clinical trials...
Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Weizmann Institute of Science
NCT07545772 · Irritable Bowel Syndrome, Constipation
NCT07540312 · IBS (Irritable Bowel Syndrome)
NCT06639984 · Irritable Bowel Syndrome
NCT06847360 · Pain, Chronic, Irritable Bowel Syndrome, and more
NCT06681012 · Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Weizmann institute of science
Rehovot
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions